PHILADELPHIA, Nov. 14, 2007 — Kibow Biotech, Inc. marked its first decade of activity by announcing today the launch of Kibow Flora(TM), the first probiotic and prebiotic combination specifically developed for Metabolic Syndrome. Metabolic Syndrome (also referred to as Syndrome-X), is a disorder affecting an estimated 22% of US adults and 4.2% of US adolescents.
In addition to Kibow Flora(TM), the Company's new Metabolic Syndrome range includes three related products – Kibow C-12 peptide, Kibow Acetyl-L-Carnitine and Kibow L-Theanine. According to the indication, each product may be taken separately or together with Kibow Flora. All ingredients in Kibow dietary supplements have been scientifically formulated and clinically validated as reported in the literature. Pricing reflects the superior quality of Kibow products.
Kibow Flora(TM) is formulated differently from Kibow Biotics(R) – the Company's premiere, patented probiotic product formulation for uremic syndrome. "We believe that Kibow Flora(TM), together with our other products addressing the multiple risk factors of metabolic syndrome, will be well-accepted in the US where Kibow has a long-established relationship with the medical community," said Dr. Natarajan Ranganathan, Kibow founder and CEO.
"Currently Kibow has begun pilot scale human clinical studies of its uremic formulation in six different sites and five countries. There exists a strong link between chronic kidney failure and Metabolic Syndrome conditions, both fast-growing health problems. Therefore the introduction of Kibow's Metabolic Syndrome product line is indeed a timely event for US consumers," said Mary Galambert, Kibow's Marketing and Communication VP.
For additional information, contact:
Dr. N. Ranganathan
Kibow Biotech, Inc.
4629 West Chester Pike
Newtown Square, PA 19073. USA
Tel: 610-353-5130, Fax: 610-353-5110
Email: Email
URL: http://www.kibow.com
Forward-Looking Statement Disclaimer: Kibow Biotech company's website contain both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, timely regulatory approval of the Company's products; the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; and the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.